Marketwire (Fri, 1:46AM)
Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
50 people get GLPYY.PK articles and Market Currents by email alert.
Get email alerts on GLPYY.PK »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
Marketwire (Fri, 1:28AM)
-
Marketwire (Mon, 11:37AM)
-
Marketwire (Apr 30, 2013)
-
Marketwire (Apr 29, 2013)
-
Marketwire (Apr 24, 2013)
-
Marketwire (Apr 23, 2013)
-
Marketwire (Apr 22, 2013)
-
Marketwire (Apr 16, 2013)
-
Marketwire (Apr 12, 2013)
-
-
Galapagos Scores With Abbott DealThe Burrill Report • Mon, Mar 5, 2012 -
To learn more about Seeking Alpha Pro, click here.
-
Galapagos Scores With Abbott DealThe Burrill Report • Mon, Mar 5, 2012
There are no Transcripts on GLPYY.PK.
-
Marketwire (Fri, 1:46AM)
-
Marketwire (Fri, 1:28AM)
-
Marketwire (Mon, 11:37AM)
-
Marketwire (Apr 30, 2013)
-
Marketwire (Apr 29, 2013)
-
Marketwire (Apr 24, 2013)
-
Marketwire (Apr 23, 2013)
-
Marketwire (Apr 22, 2013)
-
Marketwire (Apr 16, 2013)
-
Marketwire (Apr 12, 2013)
GLPYY.PK vs. ETF Alternatives
Company Description
Galapagos is a clinical stage biotech company focused on developing novel medicines. Headquartered in Belgium, the Company employs over 820 people and reported 2011 revenues of €113 million.
Galapagos’ most advanced candidate drug GLPG0634 shows excellent safety and efficacy in rheumatoid... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Wednesday, February 29, 2012, 5:07 AM Belgian drug developer Galapagos signs a deal worth up to $1.35B with Abbott Laboratories (ABT) for the development and production of an oral drug to treat arthritis and other auto-immune diseases. (PR) Comment! [Healthcare]
There are no StockTalks on this stock yet.